Skip to main content
Caplight Logo









Zymedi

Zymedi

Private
IncheonHealthcare & Life Scienceshttps://zymedi.com/

Last Round

Series A

Extension

May 30, 2023

Total Funding Raised

$28.85M

Company Overview

Zymedi is a biotechnology company that develops a novel therapeutics platform intended to improve the quality of life for people suffering from diseases by focusing on aminoacyl-tRNA synthetases (ARSs).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biopharmaceuticaldrug discoverymonoclonal antibodyaminoacyl-tRNA synthetasesARSpulmonary arterial hypertensionprecision medicinebiotechclinical-stagetherapeutic candidatedrug pipelineAI-enabled drug discoveryin-licensingpharma partneringbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Zymedi Comparables

Compare Zymedi with similar companies based on industry and business-model similarity.

Zymedi comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
aTyr Pharma
74%
Daewoong Pharmaceutical
71%
Gossamer Bio
70%

Zymedi Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionMay 30, 2023
Series AMar 26, 2021
AngelOct 1, 2020

Key People

Founding team and executive leadership

Sunghoon Kim

CEO

Executive Team

Nam Hoon Kwon

CTO EVP

Executive Team

Oliver Kim

Chief Financial Officer

Executive Team

Zymedi Investors

Notable investors and investment history

Zymedi investors
InvestorRounds
Company K Partners, LimitedSeries A, Series A Extension
CKD Venture CapitalSeries A Extension
UTC InvestmentSeries A, Series A Extension
Company K PartnersSeries A, Series A Extension
Medytox Venture InvestmentSeries A Extension
Korea Development BankSeries A Extension
Korea Venture Investment CorporationSeries A Extension

Zymedi Filings

Explore SEC and related filing metadata, where available.

Zymedi filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Zymedi's valuation, stock price, and market status.

Is Zymedi a public or private company?

Zymedi is a private company.

What is the current stock price of Zymedi?

Zymedi is a private company with no public stock price. No recent secondary market data is available.

How much is Zymedi worth (valuation)?

Valuation information for Zymedi is not publicly available.

Can I buy Zymedi stock?

Zymedi shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Zymedi's last funding round?

Zymedi's most recent funding round was Series A Extension on May 30, 2023.

Who are the main investors in Zymedi?

Key investors in Zymedi include Company K Partners, Limited, CKD Venture Capital, UTC Investment, Medytox Venture Investment, Korea Development Bank.

Will Zymedi IPO soon?

No public IPO plans have been announced for Zymedi.

How can I track Zymedi secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Zymedi's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersIncheon
Employee Range11
Year Founded2019
Last FundingMay 30, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?